Skin Care > Dermatitis / Psoriasis
COLLICORT (HIDROCORTISONA) 2.5% CREMA 60G
In stock: 16 units
THERAPEUTIC INDICATIONS: COLLICORT Lipo is indicated for contact dermatitis, atopic dermatitis, lichenification, dermatitis, stasis (varicose eczema), psoriasis, prurigo not parasitic dyshidrosis, genital lichen sclerosus et atrophicus, granuloma annulare, discoid lupus erythematosus, pustulosis palmo- no plant microbial extra-facial seborrheic dermatitis, itching caused by mycosis fungoides.
Efficortmr Lipo recommended for the treatment of scaly lesions, and inflammatory dry.
Pharmacokinetics in Humans:
COLLICORT is a high potency steroid, which acts on allergic and inflammatory processes that occur during the course of atopic dermatitis and / or contact, also acts on the itching associated with these processes. Vasoconstriction has (exudative) and antifungal to inhibit cell reproduction and synthesis processes in the dermis and epidermis.
The diesterification of hydrocortisone aceponate provides an increase in lipophilicity of hydrocortisone, which increases its ability to penetrate transcutaneously.
Hydrocortisone aceponate is catabolized in the skin by removal of hydrocortisone and esters and are not detectable in plasma.
Hydrocortisone released is metabolized by the physiological pathway of natural hydrocortisone and hexahidrogenados tetrahydrogenated derivatives in small amounts.
Plasma levels of hydrocortisone aceponate during the first week of treatment in humans, showed an increase of plasma cortisol of 162 mg / 176 g of / l which decreased to 158 mg / l during the second week of treatment, falling to 151 mg / l in the posttreatment period.
Neither the increase nor decrease in plasma cortisol levels had a statistically significant difference compared to baseline (p = 0.25, p = 0.68 and p = 0.32, respectively at weeks 1 and 2 of treatment and 1 week post-treatment). There was no data of altered hypothalamic-pituitary-adrenal.
After application of COLLICORT, systemic absorption occurs measured in terms of effect on blood cortisol levels.
The degree of absorption and systemic effects depend on the treated surface and the state of the epidermis, the duration of treatment (the longer, the greater the possibility of occurrence), the site of application, the use of occlusive dressings.
CONTRAINDICATIONS: Hypersensitivity to any component of the formula.
Acne and rosacea conditions in which the corticosteroid treatment based on skin is specifically contraindicated, visible skin infections of bacterial, viral or caused by fungi and parasites, even when they include an inflammatory response.
Use in Pregnancy and Lactation
It should avoid using COLLICORT during the first trimester of pregnancy unless the benefit that comes to justify or give this drug outweighs the potential risk to the fetus. It is unknown if the drug is excreted in human milk, so caution should be exercised when administering COLLICORT nursing mothers. In this case, the product should not be applied on the chest.
ADVERSE REACTIONS: Patients receiving high doses of potent steroids applied over a large area or under an occlusive dressing should be monitored periodically to detect if there is HPA axis suppression by analysis of urinary free cortisol and stimulation of ACTH.
If HPA axis suppression observed, lower the frequency of application or substitute a less potent steroid gradually to discontinue the corticosteroid.
Recovery of HPA axis function is generally accomplished quickly and complete cessation of drug administration.
It is rare for signs and symptoms caused by the suspension or withdrawal of steroids. If this occurs, will require additional systemic corticosteroids.
DRUG INTERACTIONS AND OTHER GENDER: Hydrolysis caused by alkaline agents: do not use alkaline antiseptic before applying COLLICORT.
Incompatible with oxidizing agents.
Concomitant use of other adrenocorticosteroids as tablets, drops or injections may increase side effects.
CHANGES IN RESULTS OF LABORATORY TESTS: No data reported to date.
PRECAUTIONS IN RELATION TO EFFECTS OF CARCINOGENESIS, MUTAGENESIS, Impairment of Fertility: No data reported to date.
DOSAGE AND ADMINISTRATION: Skin.
Adults: COLLICORT be applied one to two times a day, forming a thin layer over affected areas of skin.
For a reasonable application, apply small amounts of product in different places on the affected areas and gently massage until the product is completely absorbed.
The application should be limited to twice a day. An increase in the number of daily applications, could aggravate the side effects without improving the therapeutic efficacy of the preparation.
The treatment of large areas or long-term treatment or long-term (3 weeks or more) require clinical monitoring.
In all cases, the duration of treatment prescribed by the physician, should be strictly enforced. If necessary, the doctor may occlusive dressing.
In the case of certain dermatological conditions (psoriasis, dermatitis) is recommended to remove or discontinue the medication gradually.
This can be achieved by decreasing the frequency of application and / or with the use of a corticosteroid more dilute or less potent.
Infants and toddlers: Unless otherwise prescribed in these cases, the appropriate dose is usually one application per day.
The continuous daily treatment should be limited to a short period (about 1 week).
If the product is used for a longer period, should free intervals interspersed steroidal agents.
Occlusive dressings should be avoided in infants and young children.
REPRESENTATIONS AND MANAGEMENT Overdosage: This medicine is only for external use, if applied in excess, you will not get results faster and better.
Only intensify the undesirable effects described above.
In case of accidental ingestion gastric lavage and general supportive measures.
Name of medicine: Collicort
Comparable patent medicine: Nutracort, LOCOID
Active ingredient: Hydrocortisone
Concentration: 2.5g/100g (2.5%)
Extended-release tablets: No
Lab: Collins Laboratories, Inc. de CV
60 g tube
Made in: Mexico